Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rezolute, Inc.

5.37
-0.0100-0.19%
Volume:462.19K
Turnover:2.48M
Market Cap:466.19M
PE:-4.82
High:5.45
Open:5.37
Low:5.22
Close:5.38
Loading ...

Rezolute Inc. to Participate in BTIG Virtual Biotechnology Conference

Reuters
·
Yesterday

Rezolute Registers Secondary Offering of 1.3 Million Shares

MT Newswires Live
·
18 Jul

Rezolute files to sell 1.3M shares of common stock for holders

TIPRANKS
·
18 Jul

Rezolute Inc Files Prospectus to Resale of 1.3 Mln Shares of Common Stock by Selling Stockholders- SEC Filing

THOMSON REUTERS
·
18 Jul

Craig-Hallum Reaffirms Their Buy Rating on Rezolute (RZLT)

TIPRANKS
·
15 Jul

Rezolute Inc. Publishes Document on Phase 3 Study of Ersodetug for Congenital Hyperinsulinism

Reuters
·
15 Jul

Rezolute Inc. Announces Presentation of Phase 3 Study Baseline Data for Ersodetug in Treating Congenital Hyperinsulinism at ENDO 2025

Reuters
·
09 Jul

Rezolute Announces Presentation of Participant Baseline Data From Its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (Endo 2025)

THOMSON REUTERS
·
09 Jul

Chief Medical Officer Brian Kenneth Roberts Acquires Common Shares of Rezolute Inc

Reuters
·
26 Jun

Rezolute Inc. CFO Daron Evans Reports Acquisition of Common Shares

Reuters
·
25 Jun

Director Nerissa Kreher Reports Acquisition of Common Shares in Rezolute Inc

Reuters
·
23 Jun

Rezolute Inc. Announces $4.2 Million Private Placement with Key Investors

Reuters
·
14 Jun

BTIG Reaffirms Their Buy Rating on Rezolute (RZLT)

TIPRANKS
·
29 May

BRIEF-Rezolute Announces Completion Of Enrollment In The Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism

Reuters
·
28 May

Rezolute complete enrollment in Phase 3 sunRIZE study of ersodetug

TIPRANKS
·
28 May

Rezolute Inc - Topline Data Anticipated in December 2025

THOMSON REUTERS
·
28 May

Rezolute Announces Completion of Enrollment in the Phase 3 Sunrize Study of Ersodetug in Patients With Congenital Hyperinsulinism

THOMSON REUTERS
·
28 May

Rezolute Inc - Anticipates Bla Submission for Ersodetug in 2026

THOMSON REUTERS
·
28 May

U.S. RESEARCH ROUNDUP-Fair Issac, First Solar, UnitedHealth

Reuters
·
14 May

Rezolute Inc : Jefferies Cuts Target Price to $13 From $16

THOMSON REUTERS
·
14 May